Results 261 to 270 of about 65,249 (309)

Daratumumab in relapse-refractory immune-mediated thrombotic thrombocytopenic purpura: additional evidence for its efficacy. [PDF]

Res Pract Thromb Haemost
Coppo P.
europepmc   +1 more source

A Tale of Two: 2-Year Outcomes of 2 Patients Undergoing Compassionate Use INTREPID and TricValve System Placement: Case Series. [PDF]

J Soc Cardiovasc Angiogr Interv
Vera-Sarmiento HL, Kaneko T, Zajarias A.
europepmc   +1 more source

The efficacy of compassion focused therapy in eating disorders: a systematic review of the literature. [PDF]

J Eat Disord
Stock M, Beaman L, Moreton R, Holland-Borosh C, Hartland H, Hamadi L.   +5 more
europepmc   +1 more source

Liver Xenotransplantation: Ethical and Societal Implications. [PDF]

Xenotransplantation
Hurst DJ, Bobier CA, Padilla LA, Merlocco A, Meier RPH.   +4 more
europepmc   +1 more source

Evolving Real-World Data and Evidence Use for New Drugs and Regenerative Medical Products Approvals in Japan-An Analysis of the 6-Year Trend. [PDF]

Clin Pharmacol Ther
Okami S, Shimotsumagari K, Sadatsuki Y.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Clinical trial and compassionate use experience with glucarpidase for methotrexate toxicity.

Journal of Clinical Oncology, 2012
6530 Background: High dose methotrexate (MTX) is used to treat acute lymphoblastic leukemia (ALL), osteogenic sarcoma, non-Hodgkin lymphoma (NHL), and other cancers. MTX-associated renal impairment with delayed MTX elimination develops after 2 to 10% of treatment cycles, exposing patients to elevated MTX concentrations with potential for enhanced MTX
Brigitte C. Widemann, Nalini Jayaprakash, Scott C. Howard, Claire Daugherty, Nikhil Chauhan, Thomas King, Janet Rush   +6 more
openaire   +1 more source

Safety profile of asparaginaseErwinia chrysanthemiin a large compassionate‐use trial

Pediatric Blood & Cancer, 2014
BackgroundL‐Asparaginase is an integral component of standard chemotherapy regimens for the treatment of acute lymphoblastic leukemia (ALL). Clinical hypersensitivity, a common reason for treatment discontinuation, has been reported in 10–30% of patients receivingEscherichia coli‐derived asparaginase. After hypersensitivity,E. coli‐derived asparaginase
Paul V, Plourde, Sima, Jeha, Nobuko, Hijiya, Frank G, Keller, Lewis B, Silverman, Susan R, Rheingold, ZoAnn E, Dreyer, Gary V, Dahl, Taheri, Mercedes, Chinglin, Lai, Tim, Corn   +10 more
openaire   +2 more sources